Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 3/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.47 |
| ▸ | POLA1 | P09884 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.39 |
| ▸ | ALB | P02768 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.39 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL992410 | 0.89 | POLA1 (0.44) | PDE3APDE4DSLC29A1LMNATHRB | |
| Oleic Acid SCHEMBL581693 | 0.81 | PDE4D (0.68) | PDE3APDE4DSLC29A1LMNATHRB | |
| Elaidic Acid SCHEMBL581692 | 0.81 | PDE4D (0.68) | PDE3APDE4DSLC29A1LMNATHRB | |
| Succinic Acid SCHEMBL992636 | 0.81 | SLC28A1 (0.45) | SLC29A1 | |
| SCHEMBL15329232 | 0.80 | PDE3A (0.50) | PDE3APDE4DSLC29A1LMNATHRB | |
| SCHEMBL1880453 | 0.80 | PDE3A (0.74) | PDE3APDE4DSLC29A1LMNATHRB | |
| SCHEMBL31296447 | 0.79 | PDE3A (0.64) | PDE3APDE4DSLC29A1LMNATHRB | |
| Cetostearyl Alcohol SCHEMBL28353924 | 0.79 | PDE3A (0.80) | PDE3APDE4DSLC29A1LMNATHRB | |
| Stearic Acid SCHEMBL29059707 | 0.78 | LMNA (0.72) | PDE3APDE4DSLC29A1LMNATHRB | |
| Palmitic Acid SCHEMBL3342190 | 0.78 | LMNA (0.72) | PDE3APDE4DSLC29A1LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385337-B2 | Oligonucleotide end caps | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20170107511-A1 | OLIGONUCLEOTIDE END CAPS | BANK OF AMERICA, N.A. | 2017-04-20 | — | — | US | disclosed |
| US-9512164-B2 | Oligonucleotide end caps | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20120142101-A1 | OLIGONUCLEOTIDE END CAPS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| WO-2011005861-A9 | OLIGONUCLEOTIDE END CAPS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |
| WO-2011005861-A1 | OLIGONUCLEOTIDE END CAPS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385337-B2 | Oligonucleotide end caps | RNGTT, POLRMT, POLM | PDE3A 2470/4885PDE4D 1492/4885SLC29A1 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.